Oncology Medical Billing Services
Oncology is billed on two ledgers. One is the chair: infusion administration is a ranked hierarchy — the initial hour, each additional hour, each new drug hung after it — and a missed line is chair time delivered, never billed. The other is the drug cabinet: under buy-and-bill the practice has already paid for the agent, so a denied or under-paid line is an inventory loss, not deferred revenue, and under Medicare Part B every separately payable single-dose vial needs a wastage attestation before the claim processes. We bill both ledgers as one claim: we code the administration hierarchy off the treatment record, reconcile billed drug units to the dose administered, attach the wastage attestation to every single-dose line, and tie the authorization on file to the drug and units going out, so a regimen change that voids an approval surfaces before the infusion.
- Free audit
- No contract
- HIPAA-secure
- Cancel anytime
What do oncology billing services cover?
We bill the four places an oncology claim breaks: the chemotherapy and infusion administration hierarchy, Part B drug billing under the Average Sales Price plus 6% formula, the Medicare JW/JZ wastage attestation on single-dose vials, and payer prior authorization. On an infusion encounter those are one transaction rather than four, so we reconcile them against each other before the claim goes out rather than appealing them one line at a time afterwards. One clarification on the code table below. The single dollar figure on the initial-infusion row is the CY2026 Medicare national unadjusted non-facility amount for the administration service alone — total non-facility RVUs times the 33.4009 conversion factor in the published relative value file — before locality adjustment and separate from the drug, which is paid on ASP. The add-on and wastage rows carry no single amount because they are billed per additional hour, per sequential infusion, or per discarded milligram.
- Chemo administration is a strict hierarchy: one initial code (96413) per encounter, then add-ons
- Medicare pays most Part B drugs at ASP + 6% (about ASP + 4.3% after sequestration)
- The JZ modifier has been required on Medicare Part B single-dose-container drug claims since July 1, 2023
- Prior authorization is a recurring source of oncology treatment delay and denial
Who This Page Is For
Common Billing Friction in Oncology
The chemotherapy administration hierarchy and the single-initial-code rule
Chemotherapy administration is coded as a ranked hierarchy, not a flat list. CPT 96413 reports the initial intravenous infusion of up to one hour of a single or initial substance; 96415 is an add-on reporting each additional hour of that same infusion; 96417 reports each additional sequential infusion of a new drug. Only one initial (96413) may be reported per encounter through a single IV site, and infusion outranks push, which outranks injection. Coders who bill a second initial code, or who miss the sequential-infusion add-on on a multi-drug regimen, either trigger an edit or leave paid units on the table (CMS coverage article 53049).
Buy-and-bill drug economics on the ASP + 6% formula
In the buy-and-bill model the practice purchases the chemotherapy agent, holds it in inventory, administers it, and then bills the payer. Medicare reimburses most physician-administered Part B drugs at 106 percent of Average Sales Price — ASP plus a 6 percent add-on set in statute — which the 2 percent Medicare sequester reduces to an effective rate near ASP + 4.3 percent. Because the practice has already paid for the drug, a single denied or under-paid J-code line is a direct inventory loss, not just deferred revenue.
Medicare's JW/JZ wastage attestation on single-dose vials
CMS requires a wastage modifier on every separately payable Part B single-dose-container drug claim: JW (required since January 1, 2017) reports the amount of drug discarded and not administered, and JZ (required since July 1, 2023) attests that zero drug was wasted. From October 1, 2023, CMS has said claims for single-dose-container drugs that do not report the modifiers as appropriate may be returned as unprocessable. Oncology, which runs mostly on single-dose vials, is among the specialties most exposed to this edit.
Prior authorization as a recurring treatment-delay and denial driver
Oncology carries a heavy prior-authorization burden. In a CancerCare survey of adults with cancer (fielded September to December 2024, presented at the 2025 ASCO Quality Care Symposium), among patients who said they or their family were directly involved in obtaining prior authorization, 12 percent spent a full business week or more (41+ hours) on a single incident and 29 percent up to 2 to 3 days. Every unmanaged authorization is both a care delay and a denial waiting to happen when the drug is administered before approval posts.
Modifier discipline across drug, admin, and same-day E/M lines
An oncology claim frequently stacks a separately identifiable evaluation-and-management visit (modifier 25), a chemotherapy administration line, sequential-infusion add-ons, and a drug J-code with its wastage modifier — each with its own edit logic. Missing modifier 25 bundles the visit into the procedure; a wrong units calculation on the J-code trips Medically Unlikely Edits; a missing sequential-infusion modifier suppresses a payable add-on.
Oncology-Specific Payer Issues We Watch For
Medicare
Issue: Single-dose-vial claims without a JW or JZ modifier may be returned as unprocessable (since October 1, 2023), and Part B drug lines pay at ASP + 6% before the 2% sequester — leaving no margin for a units error.
Our approach: We attach the correct wastage modifier and documented discarded units on every single-dose claim, and reconcile billed J-code units to the administered dose before submission.
Commercial (BCBS / UnitedHealthcare / Aetna / Cigna)
Issue: Chemotherapy, immunotherapy, and supportive drugs are gated behind pathway-based prior authorization and site-of-care policies that differ by plan; administering before approval posts converts a covered service into a denial.
Our approach: We secure authorization tied to the exact drug and units, track it against the treatment calendar, and flag any regimen change that voids an existing approval.
All payers
Issue: Missing modifier 25 on a separately identifiable same-day office visit bundles the E/M into the administration; a missed sequential-infusion add-on suppresses a payable line on multi-drug regimens.
Our approach: We audit the administration hierarchy and same-day E/M on every encounter so each payable line is present and correctly modified.
What We Handle
Chemotherapy & infusion administration coding (96413 / 96415 / 96417)
We code the administration hierarchy on every encounter — one initial infusion code, correct each-additional-hour and sequential-infusion add-ons for multi-drug regimens, and the right push-versus-infusion distinction — so the chair time is fully and defensibly captured.
Part B drug (J-code) billing and units reconciliation
We reconcile the administered dose to billed J-code units against the ASP + 6% payment logic and Medically Unlikely Edit caps, so the drug the practice purchased is the drug the payer reimburses — the core of buy-and-bill margin protection.
JW/JZ single-dose-vial wastage modifiers
Every single-dose-container claim carries the correct wastage attestation — JW for discarded drug with the documented wasted units, JZ for zero waste — so claims meet the JW/JZ requirement (JZ since July 1, 2023) instead of being returned as unprocessable.
Prior authorization and payer-specific medical-necessity management
We obtain and track chemotherapy, immunotherapy, and radiation authorizations against each payer's medical-policy and pathway requirements, and align the authorization to the exact drug and units billed so administration and approval never diverge.
Radiation oncology and multi-modality claim coordination
We coordinate medical, radiation, and infusion oncology on one revenue cycle — treatment-planning, delivery, and management coding for radiation alongside medical-oncology drug and administration billing — so a multi-modality patient is billed as one clean record.
Denial appeals and underpayment recovery on high-dollar claims
Because oncology denials carry drug-level dollar amounts, we work every denied and underpaid line to appeal — reconstructing the administration hierarchy, units, and authorization trail that the original claim needed — rather than writing off a five-figure claim.
Free Billing Audit · No obligation
Is your oncology billing leaving money on the table?
We audit your last 90 days of oncology claims for under-coding, modifier errors, and denials — and show you the recoverable dollars at no cost. Written findings in 3–5 business days.
Prefer to talk? Book a 15-minute callRequest received
A billing specialist will review your practice details and reach out within 1 business day. No confirmation email is sent — if you need to reach us sooner, call +1-872-297-2815.
Key Oncology CPT Codes
| CPT Code | Description | Medicare Amount CY2026 national, non-facility |
|---|---|---|
| 96413 | Chemotherapy administration, IV infusion; up to 1 hour, single or initial substance/drug | $133 |
| 96415 | Chemotherapy IV infusion; each additional hour (add-on to 96413) | — |
| 96417 | Chemotherapy IV infusion; each additional sequential infusion of a new drug/substance, up to 1 hour (add-on) | — |
| 96409 | Chemotherapy administration; IV push, single or initial substance/drug | — |
| 96360 | IV infusion, hydration; initial, 31 minutes to 1 hour | — |
| 96375 | Therapeutic/prophylactic/diagnostic injection; each additional sequential IV push of a new drug (add-on) | — |
| 77427 | Radiation treatment management, 5 treatments | — |
| JW / JZ | Drug wastage modifiers — JW = discarded amount (required since 1/1/2017); JZ = zero waste (required since 7/1/2023) | — |
Amounts are the Medicare national unadjusted non-facility amounts for CY2026, computed from the published CMS relative value file. They are not what a commercial payer pays, and your locality adjustment moves them. A dash means Medicare publishes no amount for that code — because it is non-covered, bundled, or priced outside the fee schedule.
Why General Billing Teams Miss Oncology Issues
General billing staff handle dozens of specialties and rarely develop the depth needed for oncology coding nuances. Here is what gets missed.
Modifier and bundling errors
Specialty-specific modifier rules and CCI edits are frequently overlooked by teams that do not work exclusively in oncology.
Under-coding high-complexity visits
Oncology encounters often qualify for higher-level E/M codes, but generalist billers default to mid-level codes to avoid audit risk.
Missed payer-specific rules
Each payer has unique coverage and documentation requirements for oncology procedures that general teams rarely memorize.
Slow denial turnaround
Without specialty knowledge, appeal letters lack the clinical specificity needed to overturn oncology denials quickly.
Transition Plan
Switching billing partners should not disrupt patient care or cash flow. Our transition plan is designed for zero downtime.
Discovery and Specialty Audit
We review your current oncology billing workflows, denial patterns, and payer mix to build a tailored onboarding plan.
System Integration
We connect to your EHR and practice management system, configure specialty-specific code sets, and validate charge capture workflows.
Parallel Billing Period
We run billing in parallel with your current process for 2-4 weeks to verify accuracy before taking over completely.
Full Transition and Reporting
Once validated, we assume full billing responsibility with monthly reporting dashboards and a dedicated account manager.
Oncology Billing Terms
- Buy-and-bill
- The model in which an oncology practice purchases physician-administered drugs, holds them in inventory, administers them to the patient, and then bills the payer — putting the practice's own capital at risk on every claim.
- ASP + 6%
- The statutory Medicare Part B payment rate for most physician-administered drugs: 106 percent of the drug's Average Sales Price. The 2 percent Medicare sequester reduces the effective add-on to about 4.3 percent.
- JW / JZ modifiers
- Medicare Part B single-dose-container wastage modifiers. JW reports drug discarded and not administered; JZ attests zero waste. JZ has been required since July 1, 2023 (JW since January 1, 2017).
- Sequential infusion
- Administration of a new, different drug through the same IV access after the initial infusion, reported with add-on code 96417 — commonly missed on multi-drug chemotherapy regimens.
Last updated: 2026-10-02
Common Questions
Common questions about oncology billing services.
Request a Specialty Billing Review
See how specialty-specific billing support can improve reimbursement visibility for oncology billing services.
Request ReviewWhat CPT codes are used for chemotherapy administration?
Chemotherapy administration uses a hierarchy of CPT codes. 96413 reports the initial IV infusion of up to one hour of a single or initial drug; 96415 is an add-on for each additional hour of that infusion; 96417 reports each additional sequential infusion of a new drug. 96409 covers an IV push rather than an infusion. Only one initial administration code may be billed per encounter through a single IV line, and infusion ranks above push, which ranks above injection.
How does Medicare pay for chemotherapy drugs?
Medicare reimburses most physician-administered Part B chemotherapy drugs at the Average Sales Price plus a 6 percent add-on (106% of ASP), a rate set in statute. The 2 percent Medicare sequester reduces the effective payment to roughly ASP + 4.3 percent, as CMS describes it. Because oncology practices purchase these drugs up front under the buy-and-bill model, an incorrectly coded or denied drug line is a direct inventory loss.
What are the JW and JZ modifiers in oncology billing?
JW and JZ are drug-wastage modifiers for single-dose containers. JW reports the amount of a single-dose vial that was discarded and not administered; JZ attests that zero drug was wasted. CMS has required JZ since July 1, 2023 (JW since January 1, 2017), and its JW and JZ modifier FAQs say claims without the modifiers may be returned as unprocessable from October 1, 2023. Oncology, which runs mostly on single-dose vials, is among the specialties most affected.
Why do oncology practices lose revenue on prior authorization?
Prior authorization is a recurring source of oncology treatment delay and downstream denial. In a CancerCare survey of adults with cancer fielded in 2024 (reported by The ASCO Post, 25 October 2025), among patients directly involved in obtaining prior authorization, 12 percent spent a full business week or more (41+ hours) on a single incident and 29 percent up to 2 to 3 days. When a drug is administered before the authorization posts — or when a regimen change voids an existing approval — the high-dollar claim denies. Managing authorization against the exact billed drug and units is what prevents the loss.
Related Services
Related Specialties
Stop losing oncology margin to denials and wastage edits
Get a free review of your chemotherapy administration coding, drug-unit reconciliation, and prior-authorization workflow. We'll show you where oncology revenue is leaking and what it takes to recover it.
- No contract
- No setup fees
- Reply within 1 business day